Linda C. Burkly
About Linda C. Burkly
Executive Vice President and Chief Scientific Officer at Biogen
Linda C. Burkly holds the position of Executive Vice President and Chief Scientific Officer at Biogen, where she has dedicated over 37 years of her career. She has progressed through various roles of increasing responsibility, showcasing her expertise and leadership within the biotechnology field.
Education and Postdoctoral Experience
Linda C. Burkly completed her Ph.D. at Tufts University Graduate School of Biomedical Sciences in Boston, MA. She further enhanced her academic experience with a Postdoctoral Fellowship in the laboratory of Richard A. Flavell at Biogen Research Corp. She also earned a B.S. from Fairfield University.
Biotechnology Research Leadership
With over 35 years of experience in biotechnology, Linda C. Burkly has been a pivotal research leader at Biogen. She has invented a novel anti-CD4 mAb that was developed into Trogarzo and discovered novel VLA-4/VCAM biology, utilizing VLA-4 blockers for conditions like Crohn's disease. Linda has also been the lead on a partnered collaboration with UCB and contributed as an inventor of Dapirolizumab.
Inventor and Patent Holder
Linda C. Burkly holds 17 issued U.S. patents, demonstrating her significant contributions to the field of biotechnology. Notable projects include the development of an AAV Vector Immunogenicity and Toxicity Mitigation project and the invention of therapeutics that have had impactful applications.
Recognized Scientific Contributions
Linda C. Burkly's extensive contributions to science are highlighted by her inclusion in the Elsevier and Stanford University list of the top 2% of the most cited scientists worldwide as of August 2021. She has authored 168 publications, including 144 peer-reviewed original papers, making her a prominent figure in her field.